Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combating Antiviral Drug Resistance: A Multipronged Strategy.

Accounts of chemical research - 17 Feb 2026

Zhou Jiao, Nandi Ashim, Xu Yan, An Jing, Warshel Arieh, Huang Ziwei

Abstract excerpt

Viral proteases are essential enzymes required for viral replication and assembly, making them prime antiviral drug targets. However, under the selective pressure of protease inhibitors, viruses can acquire mutations that reduce drug binding efficacy, posing significant challenges in both chronic infections (e.g., HIV, HCV) and acute infections like COVID-19, where mutations in the SARS-CoV-2 main protease (Mpro)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Coronavirus 3C Proteases
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to TMPRSS2 gene

Share to Mutation

Share to Protease Inhibitors

Share to SARS-CoV-2

Source

Identifiers

PMID: 41650319
DOI: 10.1021/acs.accounts.5c00724

Genes

TMPRSS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combating Antiviral Drug Resistance: A Multipronged Strategy.PMID 41650319Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50.Semantic proximity Read ↗

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Semantic proximity Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read ↗

Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.Semantic proximity Read ↗

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read ↗

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read ↗

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistanceSemantic proximity Read ↗

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read ↗

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read ↗

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read ↗

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.